Table 2 Chromosome structural aberrations in patients with abnormal karyotypes

X

Xq25-qter

2 (0.74%)

9

9p12-13

2 (0.74%)

Y

Yp11.3-pter

1 (0.37%)

9q13-22

9 (3.31%)

1

1p36-pter

3 (1.10%)

9q34-qter

2 (0.74%)

1p13-32

4 (1.47%)

10

10p15-pter

2 (0.74%)

1q32-44

7 (2.57%)

11

11p15-pter

3 (1.10%)

2

2q32-33

4 (1.47%)

11q14-22

2 (0.74%)

2q36-qter

6 (2.21%)

11q23-qter

13 (4.78%)

3

3p21

4 (1.47%)

12

12p12-pter

4 (1.47%)

3q25

5 (1.84%)

13

13q14-22

4 (1.47%)

3q29-qter

5 (1.84%)

13q34-qter

4 (1.47%)

4

4p14-16

4 (1.47%)

14

14p11-pter

4 (1.47%)

4q25

3 (1.10%)

14q32-qter

18 (6.62%)

4q35-qter

3 (1.10%)

15

15q22

3 (1.10%)

5

5p14-15

6 (2.21%)

15q26-qter

7 (2.57%)

5q13-33

2 (0.74%)

16

16q24-qter

2 (0.74%)

5q35-qter

3 (1.10%)

17

17p12-13

5 (1.84%)

6

6p25-pter

5 (1.84%)

17q21

3 (1.10%)

6q13

3 (1.10%)

17q25-qter

2 (0.74%)

6q21-25

16 (5.88%)

18

18p11-pter

2 (0.74%)

6q27-qter

7 (2.57%)

18q23-qter

2 (0.74%)

7

7p13-15

2 (0.74%)

19

19p13-pter

2 (0.74%)

7p22

6 (2.21%)

20

20p13

3 (1.10%)

7q22-24

5 (1.84%)

21

21p11-pter

3 (1.10%)

8

8p22-23

6 (2.21%)

21q21-qter

3 (1.10%)

8q24

8 (2.94%)

22

22q13-qter

4 (1.47%)